First participant enrolled in CAP008 tenofovir gel implementation study
7 November 2012
Today, the Centre for the AIDS Programme of Research in South Africa (CAPRISA) enrolled its first participant in the CAPRISA 008 tenofovir gel implementation study. CAPRISA 008 will provide CAPRISA 004 trial participants with post-trial access to tenofovir gel while assessing the feasibility of providing tenofovir gel through family planning services.
Study discovers a unique feature of HIV that enables infected people to make antibodies able to kill a wide range of human immunodeficiency viruses
18 October 2012
An AIDS study published today in the journal, Nature Medicine, describes how a unique change in the outer covering of the virus found in two HIV infected South African women enabled them to make potent antibodies which are able to kill up to 88% of HIV types from around the world. This ground-breaking discovery provides an important new approach that could be useful in making an AIDS vaccine.
PROFESSOR QUARRAISHA ABDOOL KARIM RECEIVES THE 2012 TWAS PRIZE FOR MEDICAL SCIENCE
26 September 2012
Professor Quarraisha Abdool Karim has been named by the Academy of Sciences for the Developing World (TWAS), as a recipient of the Academy’s 2012 Prize for Medical Sciences “for her exceptional and distinguished contributions to HIV prevention and women's health”.
Approval of antiretroviral drug for HIV prevention brings us one step closer to ending the HIV epidemic
23 July 2012
Last week, a major milestone was reached when the US Food and Drug Administration (FDA) approved the antiretroviral (ART) drug, Truvada, to be given to sexually active, HIV-negative, high-risk individuals for use as a pre-exposure prophylaxis (PrEP), for preventing HIV infection.
ANTIRETROVIRAL PROPHYLAXIS FOR HIV PREVENTION REACHES A KEY MILESTONE – CAN SOUTH AFRICA AFFORD NOT TO IMPLEMENT PREP?
18 May 2012
On May 10, 2012 a landmark recommendation was made by a US Food and Drug Administration (FDA) Advisory Committee in support of use of the combination antiretroviral drug, TRUVADA, as a prevention tool against HIV-infection. If this recommendation is accepted by the FDA on June 15, it could pave the way for widespread implementation of pre-exposure prophylaxis (PrEP) in communities at risk of HIV infection.
CAPRISA EXPRESSES ITS SUPPORT OF “WOMENS VOICES FOR HIV PREVENTION GEL” MARCH
26 April 2012
The CAPRISA 004 Tenofovir Gel Trial was conducted from 2007 to 2010 and included about 1000 women from Durban and Vulindlela, KwaZulu-Natal. The results from this study, which were announced in July 2010 at the International AIDS Conference in Vienna, provided new hope for HIV prevention particularly for women who bear a disproportionate burden of HIV infection especially in Africa.
PROFESSORS SALIM AND QUARRAISHA ABDOOL KARIM RECEIVE THE N’GALY-MANN AWARD AND DELIVER THE OPENING LECTURE AT THE RETROVIRUS CONFERENCE IN SEATTLE ON 5 MARCH 2012
6 March 2012
The prestigious N’Galy-Mann Award was presented to Professors Quarraisha and Salim Abdool Karim in the Opening Session of the 19th Conference on Retroviruses and Opportunistic Infections (CROI) on Monday 5 March 2012 in Seattle, Washington, USA.